Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesoPher Maintenance in Mesothelioma (DENIM)
NCT03610360Phase 3Completed
- Sponsor
- Amphera B.V.
- Start
- Jun 2018
- Primary completion
- Jun 2022
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 5
01
Overview
A Phase 3 trial of MesoPher in Pleural malignant mesothelioma (MPM), sponsored by Amphera B.V.. Started Jun 2018; status: completed.
02
Drugs
MesoPher
03
Conditions
Pleural malignant mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03610360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610360.